SciClone Pharmaceuticals (Holdings) Future Growth
Future criteria checks 3/6
SciClone Pharmaceuticals (Holdings) is forecast to grow earnings and revenue by 4.7% and 12.9% per annum respectively. EPS is expected to grow by 1.3% per annum. Return on equity is forecast to be 24.1% in 3 years.
Key information
4.7%
Earnings growth rate
1.3%
EPS growth rate
| Pharmaceuticals earnings growth | 12.7% |
| Revenue growth rate | 12.9% |
| Future return on equity | 24.1% |
| Analyst coverage | Low |
| Last updated | 03 Apr 2024 |
Recent future growth updates
No updates
Recent updates
SciClone Pharmaceuticals (Holdings) Limited's (HKG:6600) 35% Price Boost Is Out Of Tune With Earnings
Apr 02
Here's Why We Think SciClone Pharmaceuticals (Holdings) (HKG:6600) Might Deserve Your Attention Today
Dec 14Estimating The Fair Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)
Jun 19SciClone Pharmaceuticals (Holdings)'s (HKG:6600) Upcoming Dividend Will Be Larger Than Last Year's
May 31Estimating The Fair Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)
Feb 17Calculating The Intrinsic Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)
Dec 02We Think You Should Be Aware Of Some Concerning Factors In SciClone Pharmaceuticals (Holdings)'s (HKG:6600) Earnings
Oct 04SciClone Pharmaceuticals (Holdings) Limited's (HKG:6600) 25% Dip In Price Shows Sentiment Is Matching Earnings
Jul 27An Intrinsic Calculation For SciClone Pharmaceuticals (Holdings) Limited (HKG:6600) Suggests It's 45% Undervalued
Jun 02Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 4,086 | 1,233 | N/A | N/A | 1 |
| 12/31/2024 | 3,610 | 1,150 | N/A | N/A | 1 |
| 12/31/2023 | 3,156 | 1,122 | N/A | N/A | N/A |
| 9/30/2023 | 3,017 | 1,038 | N/A | N/A | N/A |
| 6/30/2023 | 2,878 | 953 | 1,043 | 1,239 | N/A |
| 3/31/2023 | 2,814 | 904 | 1,015 | 1,211 | N/A |
| 12/31/2022 | 2,750 | 855 | 987 | 1,184 | N/A |
| 9/30/2022 | 2,706 | 844 | 1,107 | 1,214 | N/A |
| 6/30/2022 | 2,662 | 833 | 1,226 | 1,245 | N/A |
| 3/31/2022 | 2,590 | 878 | 1,032 | 1,137 | N/A |
| 12/31/2021 | 2,518 | 923 | 839 | 1,029 | N/A |
| 9/30/2021 | 2,259 | 837 | 506 | 840 | N/A |
| 6/30/2021 | 2,089 | 779 | 358 | 724 | N/A |
| 3/31/2021 | 2,004 | 766 | 435 | 853 | N/A |
| 12/31/2020 | 1,919 | 754 | 512 | 981 | N/A |
| 9/30/2020 | 2,001 | 817 | 657 | 974 | N/A |
| 12/31/2019 | 1,708 | 615 | 999 | 1,032 | N/A |
| 12/31/2018 | 1,409 | 535 | 143 | 167 | N/A |
| 12/31/2017 | 1,213 | 20 | 143 | 154 | N/A |
| 6/30/2017 | 1,166 | 294 | N/A | 242 | N/A |
| 3/31/2017 | 1,146 | 258 | N/A | 187 | N/A |
| 12/31/2016 | 1,112 | 213 | N/A | 240 | N/A |
| 9/30/2016 | 1,060 | 246 | N/A | 221 | N/A |
| 6/30/2016 | 1,072 | 257 | N/A | 231 | N/A |
| 3/31/2016 | 1,034 | 183 | N/A | 214 | N/A |
| 12/31/2015 | 1,021 | 191 | N/A | 211 | N/A |
| 9/30/2015 | 991 | 130 | N/A | 200 | N/A |
| 6/30/2015 | 913 | 102 | N/A | 210 | N/A |
| 3/31/2015 | 879 | 186 | N/A | 222 | N/A |
| 12/31/2014 | 836 | 156 | N/A | 171 | N/A |
| 9/30/2014 | 774 | 133 | N/A | 148 | N/A |
| 6/30/2014 | 790 | 140 | N/A | 173 | N/A |
| 3/31/2014 | 770 | 68 | N/A | 17 | N/A |
| 12/31/2013 | 769 | 66 | N/A | 58 | N/A |
| 9/30/2013 | 780 | 78 | N/A | 88 | N/A |
| 6/30/2013 | 816 | -56 | N/A | 87 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 6600's forecast earnings growth (4.7% per year) is above the savings rate (2.2%).
Earnings vs Market: 6600's earnings (4.7% per year) are forecast to grow slower than the Hong Kong market (11.7% per year).
High Growth Earnings: 6600's earnings are forecast to grow, but not significantly.
Revenue vs Market: 6600's revenue (12.9% per year) is forecast to grow faster than the Hong Kong market (8.2% per year).
High Growth Revenue: 6600's revenue (12.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 6600's Return on Equity is forecast to be high in 3 years time (24.1%)